Publish in OALib Journal
ISSN: 2333-9721
APC: Only $99

Paper Submission

Views	Downloads

Relative Articles
Poor insight in schizophrenia: neurocognitive basis.
Exploration of a genomic expression and pathway analysis approach to neurocognitive performance: preliminary findings
MicroRNA Expression Aberration as Potential Peripheral Blood Biomarkers for Schizophrenia
Neuroimaging and Neurocognitive Correlates of Aggression and Violence in Schizophrenia
Dissecting the Syndrome of Schizophrenia: Progress toward Clinically Useful Biomarkers
Schizophrenia proteomics: biomarkers on the path to laboratory medicine?
A Genetic Deconstruction of Neurocognitive Traits in Schizophrenia and Bipolar Disorder
Dissecting the Syndrome of Schizophrenia: Progress toward Clinically Useful Biomarkers
A Genome-Wide Linkage Scan for Distinct Subsets of Schizophrenia Characterized by Age at Onset and Neurocognitive Deficits
Modelos neurocognitivos en la esquizofrenia: Rol del córtex prefrontal Neurocognitive models of schizophrenia: The prefrontal cortex role
More...

PLOS ONE 2012

Characterization of Neurophysiologic and Neurocognitive Biomarkers for Use in Genomic and Clinical Outcome Studies of Schizophrenia

DOI: 10.1371/journal.pone.0039434

Gregory A. Light, Neal R. Swerdlow, Anthony J. Rissling, Allen Radant, Catherine A. Sugar, Joyce Sprock, Marlena Pela, Mark A. Geyer, David L. Braff

Full-Text Cite this paper Add to My Lib

Abstract:

Background Endophenotypes are quantitative, laboratory-based measures representing intermediate links in the pathways between genetic variation and the clinical expression of a disorder. Ideal endophenotypes exhibit deficits in patients, are stable over time and across shifts in psychopathology, and are suitable for repeat testing. Unfortunately, many leading candidate endophenotypes in schizophrenia have not been fully characterized simultaneously in large cohorts of patients and controls across these properties. The objectives of this study were to characterize the extent to which widely-used neurophysiological and neurocognitive endophenotypes are: 1) associated with schizophrenia, 2) stable over time, independent of state-related changes, and 3) free of potential practice/maturation or differential attrition effects in schizophrenia patients (SZ) and nonpsychiatric comparison subjects (NCS). Stability of clinical and functional measures was also assessed. Methods Participants (SZ n = 341; NCS n = 205) completed a battery of neurophysiological (MMN, P3a, P50 and N100 indices, PPI, startle habituation, antisaccade), neurocognitive (WRAT-3 Reading, LNS-forward, LNS-reorder, WCST-64, CVLT-II). In addition, patients were rated on clinical symptom severity as well as functional capacity and status measures (GAF, UPSA, SOF). 223 subjects (SZ n = 163; NCS n = 58) returned for retesting after 1 year. Results Most neurophysiological and neurocognitive measures exhibited medium-to-large deficits in schizophrenia, moderate-to-substantial stability across the retest interval, and were independent of fluctuations in clinical status. Clinical symptoms and functional measures also exhibited substantial stability. A Longitudinal Endophenotype Ranking System (LERS) was created to rank neurophysiological and neurocognitive biomarkers according to their effect sizes across endophenotype criteria. Conclusions The majority of neurophysiological and neurocognitive measures exhibited deficits in patients, stability over a 1-year interval and did not demonstrate practice or time effects supporting their use as endophenotypes in neural substrate and genomic studies. These measures hold promise for informing the “gene-to-phene gap” in schizophrenia research.

References

[1]	Gottesman, II, Gould TD (2003) The endophenotype concept in psychiatry: etymology and strategic intentions. Am J Psychiatry 160: 636–645.
[2]	Greenwood TA, Lazzeroni LC, Murray SS, Cadenhead KS, Calkins ME, et al. (2011) Analysis of 94 Candidate Genes and 12 Endophenotypes for Schizophrenia From the Consortium on the Genetics of Schizophrenia. Am J Psychiatry.
[3]	Greenwood TA, Light GA, Swerdlow NR, Radant AD, Braff DL (2012) Association analysis of 94 candidate genes and schizophrenia-related endophenotypes. PLoS One 7: e29630.
[4]	Braff DL, Light GA (2005) The use of neurophysiological endophenotypes to understand the genetic basis of schizophrenia. Dialogues Clin Neurosci 7: 125–135.
[5]	Bearden CE, Freimer NB (2006) Endophenotypes for psychiatric disorders: ready for primetime? Trends Genet 22: 306–313.
[6]	Turetsky BI, Calkins ME, Light GA, Olincy A, Radant AD, et al. (2007) Neurophysiological endophenotypes of schizophrenia: the viability of selected candidate measures. Schizophr Bull 33: 69–94.
[7]	Greenwood TA, Braff DL, Light GA, Cadenhead KS, Calkins ME, et al. (2007) Initial heritability analyses of endophenotypic measures for schizophrenia: the consortium on the genetics of schizophrenia. Arch Gen Psychiatry 64: 1242–1250.
[8]	Gur RE, Calkins ME, Gur RC, Horan WP, Nuechterlein KH, et al. (2007) The Consortium on the Genetics of Schizophrenia: neurocognitive endophenotypes. Schizophr Bull 33: 49–68.
[9]	Glahn DC, Almasy L, Blangero J, Burk GM, Estrada J, et al. (2007) Adjudicating neurocognitive endophenotypes for schizophrenia. Am J Med Genet B Neuropsychiatr Genet 144: 242–249.
[10]	Keefe RS, Bilder RM, Davis SM, Harvey PD, Palmer BW, et al. (2007) Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial. Arch Gen Psychiatry 64: 633–647.
[11]	Olincy A, Harris JG, Johnson LL, Pender V, Kongs S, et al. (2006) Proof-of-concept trial of an alpha7 nicotinic agonist in schizophrenia. Arch Gen Psychiatry 63: 630–638.
[12]	Light GA, Malaspina D, Geyer MA, Luber BM, Coleman EA, et al. (1999) Amphetamine disrupts P50 suppression in normal subjects. Biol Psychiatry 46: 990–996.
[13]	Umbricht D, Koller R, Vollenweider FX, Schmid L (2002) Mismatch negativity predicts psychotic experiences induced by NMDA receptor antagonist in healthy volunteers. Biol Psychiatry 51: 400–406.
[14]	Lavoie S, Murray MM, Deppen P, Knyazeva MG, Berk M, et al. (2008) Glutathione precursor, N-acetyl-cysteine, improves mismatch negativity in schizophrenia patients. Neuropsychopharmacology 33: 2187–2199.
[15]	Swerdlow NR, van Bergeijk DP, Bergsma F, Weber E, Talledo J (2009) The effects of memantine on prepulse inhibition. Neuropsychopharmacology 34: 1854–1864.
[16]	Green MF, Nuechterlein KH, Gold JM, Barch DM, Cohen J, et al. (2004) Approaching a consensus cognitive battery for clinical trials in schizophrenia: the NIMH-MATRICS conference to select cognitive domains and test criteria. Biol Psychiatry 56: 301–307.
[17]	Cho RY, Ford JM, Krystal JH, Laruelle M, Cuthbert B, et al. (2005) Functional neuroimaging and electrophysiology biomarkers for clinical trials for cognition in schizophrenia. Schizophr Bull 31: 865–869.
[18]	Braff DL, Light GA (2004) Preattentional and attentional cognitive deficits as targets for treating schizophrenia. Psychopharmacology (Berl) 174: 75–85.
[19]	Heaton RK, Gladsjo JA, Palmer BW, Kuck J, Marcotte TD, et al. (2001) Stability and course of neuropsychological deficits in schizophrenia. Arch Gen Psychiatry 58: 24–32.
[20]	Kurtz MM (2005) Neurocognitive impairment across the lifespan in schizophrenia: an update. Schizophr Res 74: 15–26.
[21]	Calkins ME, Iacono WG, Curtis CE (2003) Smooth pursuit and antisaccade performance evidence trait stability in schizophrenia patients and their relatives. Int J Psychophysiol 49: 139–146.
[22]	Hall MH, Schulze K, Rijsdijk F, Picchioni M, Ettinger U, et al. (2006) Heritability and reliability of P300, P50 and duration mismatch negativity. Behav Genet 36: 845–857.
[23]	Mathalon DH, Ford JM, Pfefferbaum A (2000) Trait and state aspects of P300 amplitude reduction in schizophrenia: a retrospective longitudinal study. Biol Psychiatry 47: 434–449.
[24]	Light GA, Braff DL (2005) Stability of mismatch negativity deficits and their relationship to functional impairments in chronic schizophrenia. Am J Psychiatry 162: 1741–1743.
[25]	Clementz BA, Sponheim SR, Iacono WG, Beiser M (1994) Resting EEG in first-episode schizophrenia patients, bipolar psychosis patients, and their first-degree relatives. Psychophysiology 31: 486–494.
[26]	First MB, Spitzer RL, Gibbon M, Williams JB (1995) Structured Clinical Interview for DSM-IV Axis I Disorders – Patient Edition (SCID-I/P, Version 2.0); Department NYBR, editor. New York: New York State Psychiatric Institute.
[27]	Maxwell E (1992) Manual for the FIGS. Bethesda, MD: National Institutes of Mental Health.
[28]	Light GA, Braff DL (2005) Mismatch negativity deficits are associated with poor functioning in schizophrenia patients. Arch Gen Psychiatry 62: 127–136.
[29]	Light GA, Hsu JL, Hsieh MH, Meyer-Gomes K, Sprock J, et al. (2006) Gamma band oscillations reveal neural network cortical coherence dysfunction in schizophrenia patients. Biol Psychiatry 60: 1231–1240.
[30]	Braff DL, Light GA, Swerdlow NR (2007) Prepulse inhibition and P50 suppression are both deficient but not correlated in schizophrenia patients. Biol Psychiatry 61: 1204–1207.
[31]	Kiang M, Braff DL, Sprock J, Light GA (2009) The relationship between preattentive sensory processing deficits and age in schizophrenia patients. Clin Neurophysiol 120: 1949–1957.
[32]	Light GA, Swerdlow NR, Braff DL (2007) Preattentive sensory processing as indexed by the MMN and P3a brain responses is associated with cognitive and psychosocial functioning in healthy adults. J Cogn Neurosci 19: 1624–1632.
[33]	Andreasen NC (1984) Scale for the Assessment of Negative Symptoms (SANS). Iowa City, Iowa: University of Iowa.
[34]	Andreasen NC (1984) Scale for the Assessment of Positive Symptoms (SAPS). Iowa City, Iowa: University of Iowa.
[35]	Hall RC (1995) Global assessment of functioning. A modified scale. Psychosomatics 36: 267–275.
[36]	Rapaport MH, Bazetta J, McAdams LA, Patterson J, Jeste DV (1996) Validation of the Scale of Functioning in older outpatients with schizophrenia. American Journal of Geriatric Psychiatry 4: 218–228.
[37]	Patterson TL, Goldman S, McKibbin CL, Hughs T, Jeste DV (2001) UCSD Performance-Based Skills Assessment: development of a new measure of everyday functioning for severely mentally ill adults. Schizophr Bull 27: 235–245.
[38]	Mausbach BT, Harvey PD, Pulver AE, Depp CA, Wolyniec PS, et al. (2010) Relationship of the Brief UCSD Performance-based Skills Assessment (UPSA-B) to multiple indicators of functioning in people with schizophrenia and bipolar disorder. Bipolar Disord 12: 45–55.
[39]	Meincke U, Light GA, Geyer MA, Braff DL, Gouzoulis-Mayfrank E (2004) Sensitization and habituation of the acoustic startle reflex in patients with schizophrenia. Psychiatry Res 126: 51–61.
[40]	Turetsky BI, Greenwood TA, Olincy A, Radant AD, Braff DL, et al. (2008) Abnormal auditory N100 amplitude: a heritable endophenotype in first-degree relatives of schizophrenia probands. Biol Psychiatry 64: 1051–1059.
[41]	Kiang M, Light GA, Prugh J, Coulson S, Braff DL, et al. (2007) Cognitive, neurophysiological, and functional correlates of proverb interpretation abnormalities in schizophrenia. J Int Neuropsychol Soc 13: 653–663.
[42]	Jahshan C, Cadenhead KS, Rissling AJ, Kirihara K, Braff DL, et al. (2011) Automatic sensory information processing abnormalities across the illness course of schizophrenia. Psychol Med. pp. 1–13.
[43]	Radant AD, Dobie DJ, Calkins ME, Olincy A, Braff DL, et al. (2007) Successful multi-site measurement of antisaccade performance deficits in schizophrenia. Schizophr Res 89: 320–329.
[44]	Horan WP, Braff DL, Nuechterlein KH, Sugar CA, Cadenhead KS, et al. (2008) Verbal working memory impairments in individuals with schizophrenia and their first-degree relatives: findings from the Consortium on the Genetics of Schizophrenia. Schizophr Res 103: 218–228.
[45]	Perry W, Heaton RK, Potterat E, Roebuck T, Minassian A, et al. (2001) Working memory in schizophrenia: transient “online” storage versus executive functioning. Schizophr Bull 27: 157–176.
[46]	Stone WS, Tsuang MT, Faraone SV, Glatt SJ, Braff DL, et al. (in submission). Impaired learning and memory on the California Verbal Learning Test (CVLT-II) in subjects with schizophrenia and their first-degree relatives: Findings from the Consortium on the Genetics of Schizophrenia. (COGS).
[47]	Braff DL, Geyer MA, Light GA, Sprock J, Perry W, et al. (2001) Impact of prepulse characteristics on the detection of sensorimotor gating deficits in schizophrenia. Schizophr Res 49: 171–178.
[48]	Swerdlow NR, Sprock J, Light GA, Cadenhead K, Calkins ME, et al. (2007) Multi-site studies of acoustic startle and prepulse inhibition in humans: initial experience and methodological considerations based on studies by the Consortium on the Genetics of Schizophrenia. Schizophr Res 92: 237–251.
[49]	Light GA, Braff DL (2001) Measuring P50 suppression and prepulse inhibition in a single recording session. Am J Psychiatry 158: 2066–2068.
[50]	Light GA, Geyer MA, Clementz BA, Cadenhead KS, Braff DL (2000) Normal P50 suppression in schizophrenia patients treated with atypical antipsychotic medications. Am J Psychiatry 157: 767–771.
[51]	Olincy A, Braff DL, Adler LE, Cadenhead KS, Calkins ME, et al. (2010) Inhibition of the P50 cerebral evoked response to repeated auditory stimuli: Results from the Consortium on Genetics of Schizophrenia. Schizophr Res.
[52]	Shrout PE (1998) Measurement reliability and agreement in psychiatry. Stat Methods Med Res 7: 301–317.
[53]	Glahn DC, Curran JE, Winkler AM, Carless MA, Kent JW, et al. (2012) High dimensional endophenotype ranking in the search for major depression risk genes. Biol Psychiatry 71: 6–14.
[54]	Hall MH, Schulze K, Rijsdijk F, Kalidindi S, McDonald C, et al. (2009) Are auditory P300 and duration MMN heritable and putative endophenotypes of psychotic bipolar disorder? A Maudsley Bipolar Twin and Family Study. Psychol Med 39: 1277–1287.
[55]	Swerdlow NR, Braff DL, Taaid N, Geyer MA (1994) Assessing the validity of an animal model of deficient sensorimotor gating in schizophrenic patients. Arch Gen Psychiatry 51: 139–154.
[56]	Woods SP, Delis DC, Scott JC, Kramer JH, Holdnack JA (2006) The California Verbal Learning Test–second edition: test-retest reliability, practice effects, and reliable change indices for the standard and alternate forms. Arch Clin Neuropsychol 21: 413–420.
[57]	Wynn JK, Green MF, Sprock J, Light GA, Widmark C, et al. (2007) Effects of olanzapine, risperidone and haloperidol on prepulse inhibition in schizophrenia patients: a double-blind, randomized controlled trial. Schizophr Res 95: 134–142.
[58]	Adler LE, Olincy A, Cawthra EM, McRae KA, Harris JG, et al. (2004) Varied effects of atypical neuroleptics on P50 auditory gating in schizophrenia patients. Am J Psychiatry 161: 1822–1828.
[59]	Nagamoto HT, Adler LE, Hea RA, Griffith JM, McRae KA, et al. (1996) Gating of auditory P50 in schizophrenics: unique effects of clozapine. Biol Psychiatry 40: 181–188.
[60]	Light GA, Braff DL (1999) Human and animal studies of schizophrenia-related gating deficits. Curr Psychiatry Rep 1: 31–40.
[61]	Adler LE, Hoffer LD, Wiser A, Freedman R (1993) Normalization of auditory physiology by cigarette smoking in schizophrenic patients. Am J Psychiatry 150: 1856–1861.
[62]	Swerdlow NR, Auerbach P, Monroe SM, Hartston H, Geyer MA, et al. (1993) Men are more inhibited than women by weak prepulses. Biol Psychiatry 34: 253–260.
[63]	Hetrick WP, Sandman CA, Bunney WE, Jin Y, Potkin SG, et al. (1996) Gender differences in gating of the auditory evoked potential in normal subjects. Biol Psychiatry 39: 51–58.
[64]	Rentzsch J, Jockers-Scherubl MC, Boutros NN, Gallinat J (2008) Test-retest reliability of P50, N100 and P200 auditory sensory gating in healthy subjects. Int J Psychophysiol 67: 81–90.
[65]	Fuerst DR, Gallinat J, Boutros NN (2007) Range of sensory gating values and test-retest reliability in normal subjects. Psychophysiology 44: 620–626.
[66]	Smith DA, Boutros NN, Schwarzkopf SB (1994) Reliability of P50 auditory event-related potential indices of sensory gating. Psychophysiology 31: 495–502.
[67]	Boutros NN, Overall J, Zouridakis G (1991) Test-retest reliability of the P50 mid-latency auditory evoked response. Psychiatry Res 39: 181–192.
[68]	Clementz BA, Geyer MA, Braff DL (1997) P50 suppression among schizophrenia and normal comparison subjects: a methodological analysis. Biol Psychiatry 41: 1035–1044.
[69]	Green MF, Kern RS, Heaton RK (2004) Longitudinal studies of cognition and functional outcome in schizophrenia: implications for MATRICS. Schizophr Res 72: 41–51.
[70]	Marder SR, Fenton W (2004) Measurement and Treatment Research to Improve Cognition in Schizophrenia: NIMH MATRICS initiative to support the development of agents for improving cognition in schizophrenia. Schizophr Res 72: 5–9.
[71]	Green MF, Nuechterlein KH (2004) The MATRICS initiative: developing a consensus cognitive battery for clinical trials. Schizophr Res 72: 1–3.
[72]	Twamley EW, Savla GN, Zurhellen CH, Heaton RK, Jeste DV (2008) Development and Pilot Testing of a Novel Compensatory Cognitive Training Intervention for People with Psychosis. Am J Psychiatr Rehabil 11: 144–163.
[73]	McGurk SR, Twamley EW, Sitzer DI, McHugo GJ, Mueser KT (2007) A meta-analysis of cognitive remediation in schizophrenia. Am J Psychiatry 164: 1791–1802.
[74]	Kawakubo Y, Kamio S, Nose T, Iwanami A, Nakagome K, et al. (2007) Phonetic mismatch negativity predicts social skills acquisition in schizophrenia. Psychiatry Res 152: 261–265.
[75]	Green MF, Nuechterlein KH, Kern RS, Baade LE, Fenton WS, et al. (2008) Functional co-primary measures for clinical trials in schizophrenia: results from the MATRICS Psychometric and Standardization Study. Am J Psychiatry 165: 221–228.
[76]	Leifker FR, Patterson TL, Bowie CR, Mausbach BT, Harvey PD (2010) Psychometric properties of performance-based measurements of functional capacity: test-retest reliability, practice effects, and potential sensitivity to change. Schizophr Res 119: 246–252.
[77]	Thompson A, Nelson B, Yung A (2011) Predictive validity of clinical variables in the “at risk” for psychosis population: international comparison with results from the North American Prodrome Longitudinal Study. Schizophr Res 126: 51–57.
[78]	Seidman LJ, Giuliano AJ, Meyer EC, Addington J, Cadenhead KS, et al. (2010) Neuropsychology of the prodrome to psychosis in the NAPLS consortium: relationship to family history and conversion to psychosis. Arch Gen Psychiatry 67: 578–588.
[79]	Jahshan C, Heaton RK, Golshan S, Cadenhead KS (2010) Course of neurocognitive deficits in the prodrome and first episode of schizophrenia. Neuropsychology 24: 109–120.
[80]	Jahshan C, Cadenhead KS, Rissling AJ, Kirihara K, Braff DL, et al. (2012) Automatic sensory information processing abnormalities across the illness course of schizophrenia. Psychol Med 42: 85–97.
[81]	Addington J, Cadenhead KS, Cannon TD, Cornblatt B, McGlashan TH, et al. (2007) North American Prodrome Longitudinal Study: a collaborative multisite approach to prodromal schizophrenia research. Schizophr Bull 33: 665–672.
[82]	Turetsky B, Colbath EA, Gur RE (1998) P300 subcomponent abnormalities in schizophrenia: II. Longitudinal stability and relationship to symptom change. Biol Psychiatry 43: 31–39.
[83]	Green MF, Butler PD, Chen Y, Geyer MA, Silverstein S, et al. (2009) Perception measurement in clinical trials of schizophrenia: promising paradigms from CNTRICS. Schizophr Bull 35: 163–181.
[84]	Swerdlow NR (2011) Are we studying and treating schizophrenia correctly? Schizophr Res 130: 1–10.

Full-Text